Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $202.9 million.

  • Puma Biotechnology's Liabilities and Shareholders Equity fell 809.12% to $202.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $807.3 million, marking a year-over-year decrease of 725.05%. This contributed to the annual value of $213.3 million for FY2024, which is 745.9% down from last year.
  • Latest data reveals that Puma Biotechnology reported Liabilities and Shareholders Equity of $202.9 million as of Q3 2025, which was down 809.12% from $194.9 million recorded in Q2 2025.
  • Puma Biotechnology's 5-year Liabilities and Shareholders Equity high stood at $260.0 million for Q2 2021, and its period low was $193.7 million during Q2 2022.
  • Over the past 5 years, Puma Biotechnology's median Liabilities and Shareholders Equity value was $205.0 million (recorded in 2024), while the average stood at $213.9 million.
  • In the last 5 years, Puma Biotechnology's Liabilities and Shareholders Equity surged by 1468.99% in 2021 and then crashed by 2551.83% in 2022.
  • Over the past 5 years, Puma Biotechnology's Liabilities and Shareholders Equity (Quarter) stood at $226.6 million in 2021, then fell by 2.0% to $222.1 million in 2022, then rose by 3.81% to $230.5 million in 2023, then dropped by 7.46% to $213.3 million in 2024, then dropped by 4.91% to $202.9 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $202.9 million for Q3 2025, versus $194.9 million for Q2 2025 and $196.2 million for Q1 2025.